-
1 Comment
BioPharma Credit PLC is currently in a long term downtrend where the price is trading 1.2% below its 200 day moving average.
From a valuation standpoint, the stock is 72.2% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 14.7.
Finally, its free cash flow fell by 0.0% to $20M since the same quarter in the previous year.
Based on the above factors, BioPharma Credit PLC gets an overall score of 1/5.
| ISIN | GB00BDGKMY29 |
|---|---|
| Sector | Financial Services |
| Industry | Asset Management |
| Exchange | LSE |
| CurrencyCode | USD |
| Target Price | None |
|---|---|
| Dividend Yield | 7.9% |
| PE Ratio | 0.09 |
| Beta | 0.1 |
| Market Cap | 100B |
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. The company debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in Leeds, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BPCR.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
